HOXB9 and cancer: Further subgroup analysis of multiple clinicopathological characteristics showed consistent upregulation of HOXB9 promoter methylation level according to patient’s age (Fig. 7B), patient’s race (Fig. 7C), patient’s weight (Fig. 7D), histological subtype (Fig. 7E), individual cancer stage (Fig. 7F), tumor grade (Fig. 7G), and TP53 mutation status (Fig. 7H).